INTRODUCTION: Standard therapy for limited-stage small-cell lung cancer (L-SCLC) is concurrent chemotherapy and radiotherapy (RT) followed by prophylactic cranial radiotherapy. Although many consider the standard RT regimen to be 45 Gy in 1.5 Gy twice-daily fractions, this has failed to gain widespread acceptance. We pooled data of patients assigned to receive daily RT of 70 Gy from three, consecutive prospective Cancer and Leukemia Group B L-SCLC cancer trials and report the results here. METHODS: All patients from consecutive Cancer and Leukemia Group B L-SCLC trials (39808, 30002, and 30206) using high-dosage daily RT with concurrent chemotherapy were included, and analyzed for toxicity, disease control, and survival. Overall survival (OS) and progression-free survival (PFS) were modeled using Cox proportional hazards models. Prognostic variables for OS-rate and PFS-rate were assessed using logistic regression model. RESULTS: Two hundred patients were included. The median follow-up was 78 months. Grade 3 or greater esophagitis was 23%. The median OS for pooled population was 19.9 months (95% confidence interval [CI]: 16.7-22.3), and 5-year OS rate was 20% (95% CI: 16-27%). The 2-year PFS was 26% (95% CI: 21-32%). Multivariate analysis found younger age (p = 0.02; hazard ratio [HR]: 1.023; 95% CI: 21-32), and female sex (p = 0.02; HR:0.69; 95% CI: 0.50-0.94) independently associated with improved overall survival. CONCLUSION: Two-Gy daily RT to a total dosage of 70 Gy was well tolerated with similar survival to 45 Gy (1.5 Gy twice-daily). This experience may aid practitioners decide whether high-dosage daily RT with platinum-based chemotherapy is appropriate outside of a clinical trial.
INTRODUCTION: Standard therapy for limited-stage small-cell lung cancer (L-SCLC) is concurrent chemotherapy and radiotherapy (RT) followed by prophylactic cranial radiotherapy. Although many consider the standard RT regimen to be 45 Gy in 1.5 Gy twice-daily fractions, this has failed to gain widespread acceptance. We pooled data of patients assigned to receive daily RT of 70 Gy from three, consecutive prospective Cancer and Leukemia Group B L-SCLC cancer trials and report the results here. METHODS: All patients from consecutive Cancer and Leukemia Group B L-SCLC trials (39808, 30002, and 30206) using high-dosage daily RT with concurrent chemotherapy were included, and analyzed for toxicity, disease control, and survival. Overall survival (OS) and progression-free survival (PFS) were modeled using Cox proportional hazards models. Prognostic variables for OS-rate and PFS-rate were assessed using logistic regression model. RESULTS: Two hundred patients were included. The median follow-up was 78 months. Grade 3 or greater esophagitis was 23%. The median OS for pooled population was 19.9 months (95% confidence interval [CI]: 16.7-22.3), and 5-year OS rate was 20% (95% CI: 16-27%). The 2-year PFS was 26% (95% CI: 21-32%). Multivariate analysis found younger age (p = 0.02; hazard ratio [HR]: 1.023; 95% CI: 21-32), and female sex (p = 0.02; HR:0.69; 95% CI: 0.50-0.94) independently associated with improved overall survival. CONCLUSION: Two-Gy daily RT to a total dosage of 70 Gy was well tolerated with similar survival to 45 Gy (1.5 Gy twice-daily). This experience may aid practitioners decide whether high-dosage daily RT with platinum-based chemotherapy is appropriate outside of a clinical trial.
Authors: Keith L Miller; Lawrence B Marks; Gregory S Sibley; Robert W Clough; Jennifer L Garst; Jeffrey Crawford; Timothy D Shafman Journal: Int J Radiat Oncol Biol Phys Date: 2003-06-01 Impact factor: 7.038
Authors: J P Pignon; R Arriagada; D C Ihde; D H Johnson; M C Perry; R L Souhami; O Brodin; R A Joss; M S Kies; B Lebeau Journal: N Engl J Med Date: 1992-12-03 Impact factor: 91.245
Authors: Jeffrey A Bogart; James E Herndon; Alan P Lyss; Dorothy Watson; Antonius A Miller; Michael E Lee; Andrew T Turrisi; Mark R Green Journal: Int J Radiat Oncol Biol Phys Date: 2004-06-01 Impact factor: 7.038
Authors: P Coy; I Hodson; D G Payne; W K Evans; R Feld; A S MacDonald; D Osoba; J L Pater Journal: Int J Radiat Oncol Biol Phys Date: 1988-02 Impact factor: 7.038
Authors: B Movsas; J Moughan; R Komaki; H Choy; R Byhardt; C Langer; M Goldberg; M Graham; D Ettinger; D Johnstone; R Abrams; R Munden; G Starkschall; J Owen Journal: J Clin Oncol Date: 2003-11-03 Impact factor: 44.544
Authors: Steven E Schild; James A Bonner; Thomas G Shanahan; Burke J Brooks; Randolph S Marks; Susan M Geyer; Shauna L Hillman; Gist H Farr; Henry D Tazelaar; James E Krook; Francois J Geoffroy; Muhammad Salim; Robert M Arusell; James A Mailliard; Paul L Schaefer; James R Jett Journal: Int J Radiat Oncol Biol Phys Date: 2004-07-15 Impact factor: 7.038
Authors: N Murray; P Coy; J L Pater; I Hodson; A Arnold; B C Zee; D Payne; E C Kostashuk; W K Evans; P Dixon Journal: J Clin Oncol Date: 1993-02 Impact factor: 44.544
Authors: Michael J Kelley; Jeffrey A Bogart; Lydia D Hodgson; Rafat H Ansari; James N Atkins; Herbert Pang; Mark R Green; Everett E Vokes Journal: J Thorac Oncol Date: 2013-01 Impact factor: 15.609
Authors: Amir Zahra; Tangel Chang; Taher Abu Hejleh; Muhammad Furqan; Gerald H Clamon; Sudershan K Bhatia; John M Watkins; Sarah L Mott; Logan L Ahmann; Kellie L Bodeker; Douglas R Spitz; John M Buatti; Bryan G Allen Journal: J Oncol Transl Res Date: 2016-07-26
Authors: Thomas E Stinchcombe; Wen Fan; Steven E Schild; Everett E Vokes; Jeff Bogart; Quynh-Thu Le; Charles R Thomas; Martin J Edelman; Leora Horn; Ritsuko Komaki; Harvey J Cohen; Apar Kishor Ganti; Herbert Pang; Xiaofei Wang Journal: Cancer Date: 2018-10-21 Impact factor: 6.860